Gilead Sciences, Inc. v. Safe Chain Solutions, LLC

District Court, E.D. New York·Decided August 29, 2024·No. 1:21-cv-04106·Unknown

Opinion

UNITED STATES DISTRICT COURT EASTERN DISTRICT OF NEW YORK --------------------------------------------------------------------- x GILEAD SCIENCES, INC., GILEAD SCIENCES IRELAND UC, and GILEAD SCIENCES LLC, SEALED REPORT AND Plaintiffs, RECOMMENDATION1

-against- 21-CV-4106 (Donnelly, J.) SAFE CHAIN SOLUTIONS LLC, et al., (Marutollo, M.J.)

Defendants. --------------------------------------------------------------------- x

JOSEPH A. MARUTOLLO, United States Magistrate Judge: On March 19, 2024, Plaintiffs Gilead Sciences, Inc., Gilead Sciences Ireland UC, and Gilead Sciences LLC (together, “Gilead”) filed a Contempt Motion, styled as a “Motion for Order to Show Cause for Contempt” seeking an order from this Court finding Defendant Yisel Lopez (“Ms. Lopez”) liable for violating the terms of an Asset Freeze Order entered on August 11, 2022. Dkt. No. 1327. In its memorandum of law in support of its contempt motion, Gilead asserts that it has learned from third-party discovery that Ms. Lopez entered into a contract for the sale of a property subject to the Asset Freeze Order. Dkt. No. 1328, at 4. Gilead seeks an order ensuring that Ms.

1 Certain exhibits filed with Gilead’s Contempt Motion are under seal. “That is at odds with the principles of public access and transparency.” Lyons v. New York Life Ins. Co., No. 20-CV-3120 (PAE), 2022 WL 837202, at *27 (S.D.N.Y. Mar. 21, 2022), appeal dismissed (Oct. 21, 2022) (“on its review of the summary judgment record, the Court found documents that were improperly filed under seal or redacted.”); see also AngioDynamics, Inc. v. C.R. Bard, Inc., No. 17-CV-598 (BKS) (CFH), 2022 WL 2643583, at *26 (N.D.N.Y. July 8, 2022) (“Portions of a number of the exhibits refer portions of many of these documents are quoted publicly elsewhere in the record, suggesting that maintaining these documents entirely under seal is not justified.”). Nonetheless, at this time and out of an abundance of caution, the Court is issuing this Report and Recommendation under seal with copies provided to the parties. The parties may submit a copy of this Report and Recommendation with proposed redactions by September 5, 2024. If the parties do not submit any proposed redactions by September 5, 2024, the Court will docket this Report and Recommendation, in its entirety, on the public docket. Lopez is not able to dissipate the proceeds of this sale—along with additional relief “to address her prior violations of the Asset Freeze Order.” Id. Specifically, Gilead alleges that three violations of the Asset Freeze Order have already occurred: (i) the sale of a Miami property by Ms. Lopez, (ii) the mortgaging of her primary residence in Broward County, Florida, and (iii)

contracting for the sale of her primary residence in Broward County, Florida. Id. Following a referral2 from the Honorable Ann M. Donnelly, United States District Judge, the undersigned respectfully recommends that (i) Gilead’s Contempt Motion be GRANTED; (ii) Ms. Lopez be held in contempt and, as a remedy, and (iii) that Ms. Lopez be directed to comply with the directives outlined in Section IV of this Report and Recommendation. I. BACKGROUND A. Relevant Facts This action, which commenced on July 22, 2021, arises out of an alleged HIV drug counterfeiting ring involving three groups of participants: suppliers, distributors, and pharmacies. See Memorandum Decision and Order, Dkt. No. 781 at 2; see also Fourth Amended Complaint,

Dkt. No. 782 ¶¶ 1-11. Gilead alleges that distributor defendants sold “authentic-looking” Gilead- branded bottles repurposed with non-Gilead drugs, such as anti-psychotic medication, that do not treat HIV. Id at ¶¶ 1-2, 204-208. Gilead also alleges that defendants sold thousands of Gilead- branded bottles with the correct Gilead medication but accompanied by fake government-required forms called “pedigrees.” Id. at ¶¶ 216-219. Since Gilead is in the business of, inter alia,

2 The undersigned notes, in the interest of clarity, that Gilead’s Contempt Motion stems from an alleged violation of a district judge’s order and does not implicate a magistrate judge’s contempt authority as outlined in 28 U.S.C. § 636(e). See Aquavit Pharms., Inc. v. U-Bio Med, Inc., No. 19-CV-3351 (VEC), 2020 WL 1900502, at *4 n.2 (S.D.N.Y. Apr. 17, 2020). Therefore, the undersigned’s opinion is issued as a Report and Recommendation to the district judge and will be regarded as any other proposed findings of fact and recommended dispositions issued under 28 U.S.C. § 636(b)(1) and Rule 72(b)(1). See id.; Funnekotter v. Republic of Zimbabwe, No. 09-CV-8168, 2011 WL 5517860, at *2 (S.D.N.Y. Nov. 10, 2011). producing “life-saving treatments for patients living with HIV” and “pre-exposure prophylactic, or PrEP, medication that protects against HIV-1 infection when taken as prescribed,” (id. at ¶¶ 1, 190), the consequences of Defendants’ alleged conduct can be—as Gilead posits—“dire.” Id. at ¶ 3. Further, since the foreign drugs in the counterfeit bottles were not obtained via proper

prescriptions and since individuals who received and ingested these counterfeits “unwittingly miss[ed] their HIV treatment or falsely believe[d] themselves to be protected against HIV infection,” Gilead commenced this action with a heightened interest in putting “an immediately stop to the sale of these dangerous counterfeit medications.” Id. at ¶ 12. Gilead seeks, inter alia, injunctive and monetary relief against all Defendants for trademark infringement in violation of Section 32 of the Lanham Act (15 U.S.C. § 1114); false descriptions and false designations of origin in commerce in violation of Section 43 of the Lanham Act (15 U.S.C. § 1125); trademark dilution in violation of Section 43 of the Lanham Act (15 U.S.C. § 1125) and New York General Business Law § 360-1; deceptive business practices in violation of New York General Business Law § 349; common-law unjust enrichment and unfair competition;

engaging in a pattern of racketeering activity in violation of RICO, 18 U.S.C. § 1962(c); and conspiracy to engage in a pattern of racketeering activity in violation of RICO, 18 U.S.C. § 1962(d). Id. at ¶¶ 652-749. B. The Asset Freeze Order On July 30, 2022, Gilead moved to amend its Third Amended Complaint to “add new Defendants and to add new allegations concerning existing Defendants, and the counterfeiting conspiracy, based on new evidence.” Dkt. No. 606, at 1. In addition, Gilead also moved for (i) an ex parte seizure order “permitting the seizure of dangerous counterfeit HIV medications and the documentation concerning their purchase, sale, and distribution”; (ii) an temporary restraining order, to be following a preliminary injunction, “enjoining certain newly added Defendants from the manufacture, sale, distribution, and advertisement of Gilead drug”; and (iv) an asset freeze order against certain newly added Defendants “to preserve Gilead’s right to an equitable accounting.” Id. In support of its motion to amend, Gilead submitted a proposed Fourth Amended

Complaint naming, inter alia, Mr. Herrera and Ms. Lopez as “newly-added” defendants in this action. See Dkt. No. 606-1 (Proposed Fourth Amended Complaint); 606-5 (Redline to the Third Amended Complaint).

Free access — add to your briefcase to read the full text and ask questions with AI

Gilead Sciences, Inc. v. Safe Chain Solutions, LLC, (E.D.N.Y. 2024).

Gilead Sciences, Inc. v. Safe Chain Solutions, LLC (Gilead Sciences, Inc. v. Safe Chain Solutions, LLC) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

Ex Parte Robinson
86 U.S. 505 (Supreme Court, 1874)
Thomas v. Arn
474 U.S. 140 (Supreme Court, 1986)
Chambers v. Nasco, Inc.
501 U.S. 32 (Supreme Court, 1991)
Eli Lilly & Co. v. Gottstein
617 F.3d 186 (Second Circuit, 2010)
Waffenschmidt v. Mackay
763 F.2d 711 (First Circuit, 1985)
People v. Terry
45 F.3d 17 (Second Circuit, 1995)
CBS Broadcasting Inc. v. FilmOn.com, Inc.
814 F.3d 91 (Second Circuit, 2016)
Next Investments, LLC v. Bank of China
12 F.4th 119 (Second Circuit, 2021)
John Wiley & Sons, Inc. v. Book Dog Books, LLC
327 F. Supp. 3d 606 (S.D. Illinois, 2018)
Gucci America, Inc. v. Bank of China
768 F.3d 122 (Second Circuit, 2014)
O'Toole v. Wrobel (In re Sledziejowski)
533 B.R. 408 (S.D. New York, 2015)
Hunter TBA, Inc. v. Triple V Sales
250 F.R.D. 116 (E.D. New York, 2008)